ScripThe hemophilia market is a challenging and competitive field but Sanofi is confident that fitusiran, which has just been given the green light by the US Food and Drug Administration (28 March), has th
ScripPfizer’s recent exit from gene therapies was not an indictment of the safety and efficacy of gene and cellular therapies. Rather it was the latest example of the difficulties in commercializing these
ScripCSL’s Opening And Closing Doors Near the end of fourth-quarter 2024 earnings season for life science companies, Australia’s CSL reported its half-year results. Its stock price initially increased by a
Pink SheetHemgenix (etranacogene dezaparvovec), CSL Behring’s one-time gene therapy for hemophilia B, is being made available to patients in various European countries, thanks to “innovative access decisions” f